Our work is not the first to show a MEK-independent activation of ERK1/2, Aksamitiene et al. (2010), have demonstrated that ERK1/2 can be activated in a MEK-independent, but PI3K/Akt-sensitive fashion, in the ER-positive breast cancer cell line T47D [69]. The gene discussed is MAPK3; the disease is breast cancer.